PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-116.92%
Negative EBIT growth while CRVO is at 93.99%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-185.87%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-92.79%
Negative net income growth while CRVO stands at 93.75%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-3998.91%
Negative EPS growth while CRVO is at 93.31%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-3998.91%
Negative diluted EPS growth while CRVO is at 93.31%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-95.29%
Share reduction while CRVO is at 1.27%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-95.29%
Reduced diluted shares while CRVO is at 1.27%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
75.47%
Positive OCF growth while CRVO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
66.24%
Positive FCF growth while CRVO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-141.36%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-420.27%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-362.87%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-427041.90%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-659606.65%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-1088784.48%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
-4964.64%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-1566.95%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1993307.75%
Asset growth above 1.5x CRVO's 6.34%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
57821.37%
Positive BV/share change while CRVO is negative. John Neff sees a clear edge over a competitor losing equity.
2.24%
Debt shrinking faster vs. CRVO's 19.87%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
178.96%
R&D growth of 178.96% while CRVO is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
203.49%
We expand SG&A while CRVO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.